Trial ID or NCT#

NCT02537548

Status

RECRUITING

Purpose

This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.

Official Title

Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)

Eligibility Criteria

Ages Eligible for Study: Older than 16 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No

Investigator(s)

Eila C. Skinner
Urologic oncologist, Urologist
Thomas A. Stamey Research Professor in Urology
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) at the Stanford University Medical Center
Harcharan Gill
Urologic oncologist, Urologist, Genitourinary specialist
Kathryn Simmons Stamey Professor

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061